January 3, 2019 10:27 AM EST
R&D
Pharma

Af­ter blue­print­ing R&D hub, Ab­b­Vie dish­es out $105M for CD39 pact with Tizon­a's new CEO from Roche

Amber Tong

With the $10 bil­lion Ro­va-T pro­gram seem­ing­ly head­ed to­ward the cliff, Ab­b­Vie is turn­ing to an ear­ly-stage col­lab­o­ra­tion for a longer shot at can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

A service from the Financial Times